Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov 21;19(11):e0298509.
doi: 10.1371/journal.pone.0298509. eCollection 2024.

Serological survey in a university community after the fourth wave of COVID-19 in Senegal

Affiliations

Serological survey in a university community after the fourth wave of COVID-19 in Senegal

Fatou Thiam et al. PLoS One. .

Abstract

A cross-sectional survey was conducted at Polytechnic High School (PHS) to assess the spread of COVID-19 infection among students and staff. A random cluster sampling was conducted between May 19 and August 18, 2022, after the fourth wave of COVID-19 in Senegal. IgM and IgG SARS-CoV-2 antibodies were screened using WANTAI SARS-CoV-2 ELISA assays. Seroprevalence and descriptive statistics were calculated, and associations between seropositivity and different factors were determined using logistic regression. A total of 637 participants were recruited and the median age was 21 years [18-63]. 62.0% of the participants were female, and 36.89% were male, with a male-to-female ratio = 0.59. The overall IgG and IgM seroprevalence were 92% and 6.91% respectively. Among those who tested positive for IgM, 6.75% were also positive for IgG, and 0.15% were negative for IgG. Interestingly, 6.90% of participants tested negative for both IgM and IgG. We found a higher IgM seroprevalence in men than women (9.4% vs. 5.6%) and a lower IgM seroprevalence in (18-25) age group compared to (55-65) years. We revealed a significant difference according to IgG seroprevalence among participants who declared fatigue symptoms [92.06% (95% CI: 89.96-94.16)] compared to those who did not [80.39% (95% CI: 77.31-83.47)], p = 0.0027. IgM seropositivity was found to be associated with Body Mass Index (BMI) categories (O.R. 0.238, p = 0.043), ethnic group (O.R. 0.723, p = 0.046), and marital status (O.R. 2.399, p = 0.021). Additionally, IgG seropositivity was linked to vaccination status (O.R. 4.741, p < 0.001). Our study found that most students and staff at PHS were exposed to SARS-CoV-2, confirming the virus's circulation at the time of the survey. We also identified differences in individual susceptibility that need further clarification. Our results highlight the importance of seroepidemiological surveys to assess the true impact of the COVID-19 pandemic in a community and to monitor variations in antibody response.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Flowchart of participants’ enrolment for the anti-SARS-CoV-2 antibody seroprevalence study in Superior Polytechnic School from May 19 to August 18, 2022.
Fig 2
Fig 2. Compliance with preventive measures recommended by authorities.
An interviewer-administered questionnaire was distributed to participants, containing questions about compliance with WHO’s recommended preventive measures, and then the rate of responses was determined. A) Responses related to the frequency of personal hygiene and physical distancing; and B) social distancing in the last 15 days before the survey. Values below bars indicate specific percentages.
Fig 3
Fig 3. Diagnosis and clinical symptoms related to COVID-19.
A) Relative frequency distribution (%) of different clinical diagnostics of COVID-19 and; B) symptoms of COVID-19, show that most symptoms were headaches, Fatigue or Weakness and runny nose, in respondents of our study. Notes: The values are shown in percentage.

Similar articles

References

    1. Asselah T, Durantel D, Pasmant E, Lau G, Schinazi RF. COVID-19: Discovery, diagnostics and drug development. J Hepatol. 2021;74(1):168–84. Epub 20201008. doi: 10.1016/j.jhep.2020.09.031 - DOI - PMC - PubMed
    1. Yesudhas D, Srivastava A, Gromiha MM. COVID-19 outbreak: history, mechanism, transmission, structural studies and therapeutics. Infection. 2021;49(2):199–213. Epub 20200904. doi: 10.1007/s15010-020-01516-2 - DOI - PMC - PubMed
    1. WHO Director-General’s opening remarks at the media briefing on COVID19 -March 2020.
    1. https://www.worldometers.info/coronavirus/ (accessed November 12, 2023).
    1. Mofijur M, Fattah IMR, Alam MA, Islam A, Ong HC, Rahman SMA, et al.. Impact of COVID-19 on the social, economic, environmental and energy domains: Lessons learnt from a global pandemic. Sustain Prod Consum. 2021;26:343–59. Epub 20201014. doi: 10.1016/j.spc.2020.10.016 - DOI - PMC - PubMed